HANMI - Well-suited to success
Korea's aging population and a rise in economic well-being and health-care awareness has fostered a climate for pharmaceutical firms such as Hanmi to prosper. While the company's fourth quarter earnings fell below consensus forecasts, its ambition remains to become market leader both at home and abroad. Chris Wright reports.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts